연구 및 보고서
2026년 9월 14일•1분 읽기
Altheogen signs fourth ALT‑B4 licensing deal of 2024 with Novartis
Altheogen announced an exclusive option and license agreement with Novartis for its ALT‑B4 hyaluronidase platform, marking its fourth such deal this year as pharma firms shift from IV to subcutaneous formulations.
연구 및 보고서
2026년 8월 30일•1분 읽기
Targeted Therapies Transform Atopic Dermatitis Treatment
Emerging targeted drugs are shifting atopic dermatitis care from symptom control to broader quality‑of‑life improvements.